Emergent BioSolutions (EBS) Total Non-Current Liabilities (2010 - 2026)
Emergent BioSolutions (EBS) posted Total Non-Current Liabilities of $740.0 million for Q2 2026, down 2.06% on a QoQ basis from $755.6 million in Q1 2026, and down 12.05% year-over-year from $841.4 million in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Emergent BioSolutions has reported Total Non-Current Liabilities for 17 years, with the latest figure at $740.0 million in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 12.05% year-over-year to $740.0 million in Q2 2026; TTM through Jun 2026 was $740.0 million, a 12.05% decrease from a year earlier, with the FY2025 full-year figure at $742.1 million, down 14.48% from the prior year.
- Total Non-Current Liabilities was $740.0 million for Q2 2026 at Emergent BioSolutions, down from $755.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.7 billion in Q4 2022, with the low at $740.0 million in Q2 2026.
- Average Total Non-Current Liabilities over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities soared 49.08% in 2023, then sank 35.48% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $1.7 billion in 2022, then slumped by 34.09% to $1.1 billion in 2023, then fell by 24.21% to $867.8 million in 2024, then decreased by 14.48% to $742.1 million in 2025, then fell by 0.28% to $740.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $740.0 million (Q2 2026), $755.6 million (Q1 2026), and $742.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | 60.97 Bn |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | 32.04 Bn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | 1.88 Bn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | 1.53 Bn |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | 740.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 740.00 Mn |
| Mar 31, 2026 | 755.60 Mn |
| Dec 31, 2025 | 742.10 Mn |
| Sep 30, 2025 | 835.90 Mn |
| Jun 30, 2025 | 841.40 Mn |
| Mar 31, 2025 | 838.00 Mn |
| Dec 31, 2024 | 867.80 Mn |
| Sep 30, 2024 | 933.60 Mn |
| Jun 30, 2024 | 1.10 Bn |
| Mar 31, 2024 | 1.11 Bn |
| Dec 31, 2023 | 1.15 Bn |
| Sep 30, 2023 | 1.16 Bn |
| Jun 30, 2023 | 1.20 Bn |
| Mar 31, 2023 | 1.72 Bn |
| Dec 31, 2022 | 1.74 Bn |
| Sep 30, 2022 | 1.41 Bn |
| Jun 30, 2022 | 1.16 Bn |
| Mar 31, 2022 | 1.16 Bn |
| Dec 31, 2021 | 1.28 Bn |
| Sep 30, 2021 | 1.29 Bn |
API Access
Emergent BioSolutions Total Non-Current Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "total-non-current-liabilities", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();